Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, Thomas Roth, David Mayleben et al.|The Lancet Neurology|2022Cited by 240
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia DisorderYves Dauvilliers, Jan Hedner, Dalma Seboek Kinter et al.|Annals of Neurology|2020Cited by 145
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorderGary Zammit, Dieter Kunz, D. Sebök Kinter et al.|Neurology|2020Cited by 103
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled TrialIngo Fietze, W. Vaughn McCall, Claudio L. Bassetti et al.|Drugs & Aging|2022Cited by 55
P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric CancerKun‐Huei Yeh, Zev A. Wainberg, Lisa Nardi et al.|Annals of Oncology|2012Cited by 1